Manufacturing and Production

Showing 15 posts of 5882 posts found.

France to push for drug price control regulations at upcoming G7 summit

May 3, 2016 Manufacturing and Production Drug pricing, France, drug prices, g7 summit, hollande, irreversible, medicines, pharmaceutical, prices

France will urge its fellow G7 partners to introduce strict and final new limits to control the prices of new …
stocks1

Weekly Movers: Neuren Pharma, Eli Lilly, Gilead Sciences…

May 3, 2016 Manufacturing and Production

Corporate result announcements remained the key focus as well as the primary drivers for stock movements this week as the …
regeneron

Regeneron says trial drug for osteoarthritis pain meets primary endpoint in Phase II trials

May 3, 2016 Manufacturing and Production, Research and Development Phase II, Regeneron Pharmaceuticals, drug trial, osteoarthritis, phase III

Regeneron Pharmaceuticals (Nasdaq: REGN) said mid-stage trials for its drug candidate to treat osteoarthritis pain med its primary endpoint. The …
bill_ackman

Big investor hits back at critics as Valeant’s war of words gathers pace

May 3, 2016 Manufacturing and Production, Sales and Marketing Valeant, ackman, allegations, buffett, practices, price gouging, price rises, scandal

Valeant have hit the mainstream news again after key investor Bill Ackman mounted a robust defence of the company, ruling …
v2_crestor_10_mg

Allergan launches Crestor generic in the US

May 3, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Allergan, AstraZeneca, Crestor, FDA, FDA Approval, cholesterol, generic, patent, patent expiry, sales

Allergan has received FDA approval on the generic version of AstraZeneca’s high cholesterol drug, Crestor (rosuvastatin), and has become the …
mylan_building

Mylan Q1 revenue up 17%, maintains FY view

May 3, 2016 Manufacturing and Production, Sales and Marketing Financial, Mylan, Q1, results, revenue, sales

Pharma firm Mylan NV (Nasdaq: MYL) on Tuesday reported a 17% rise in first-quarter revenue and said it maintains its …
novartis_afinitor

Afinitor receives EU recommendation to treat rare lung cancer

April 29, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Afinitor, Novartis

Novartis has received a recommendation from the Committee for Medicinal Products for Human Use at the European Medicines Agency for …
sanofi_hq__boetie_hall

Sanofi confirm 2016 outlook with Q1 results, EPS rises 5.3%

April 29, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2016, Q1, Sanofi, earnings, outlook, results

Sanofi (EPA: SAN) has confirmed its outlook for 2016 with the publication of their first quarter results, with earnings per …
amgen_hq

Amgen raises 2016 outlook after Q1 earnings boost

April 29, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Enbrel, etanercept, financial results, financials, sales rise

Amgen (NASDAQ: AMGN) has upgraded their 2016 outlook after posting an increase of 10% in revenues for the first quarter …
abbvie_0

AbbVie expands oncology portfolio with $5.8 billion Stemcentrx acquisition

April 29, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, acquisition, rova-t, stremcentrx, takeover

AbbVie (NYSE: ABBV) has announced the acquisition of Stemcentrx, and its lead late stage, lung cancer candidate Rova-T (rovalpituzumab tesirine), …
abbottweb

Abbott to purchase St Jude Medical in $25 billion deal

April 28, 2016 Manufacturing and Production, Research and Development, Sales and Marketing $25, 25 billion, Abbott, Medical device, acquisition, purchase, st jude medical

Abbott (NYSE: ABT) has announced an agreement to purchase device manufacturer, St Jude Medical, in a deal worth $25 billion. …
j

Valeant’s outgoing boss tells Senate committee he “regrets” drug price rises

April 28, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Senate, Valeant, admits, aggressive, committee, drug price, pearson, rises

Outgoing Valeant (NYSE: VRX) boss, Michael Pearson, expressed regret at the way his company conducted operations to a US Senate …

SHL at the 2016 Prefillied Syringes Seminar Tokyo

April 28, 2016 Manufacturing and Production

 SHL is glad to announce that it is going to participate in the Prefilled Syringe Seminar 2016 Tokyo, organized by …
shirelabsus

Shire to close Hampshire base and relocate jobs, say reports

April 27, 2016 Manufacturing and Production, Research and Development Jobs, Shire, close, factory, hampshire, loss, relocate

Shire is set to cease operations at its site in Basingstoke, Hampshire, by the end of next year and relocate …
The Gateway to Local Adoption Series

Latest content